T-DM1 has significantly enhanced the prognosis of HER-2-positive breast cancer patients who fail to achieve a pathological complete response or develop distant metastases after neoadjuvant trastuzumab and pertuzumab therapy. Here, ERBB2 is linked to breast carcinoma.